Tempest Therapeutics (TPST) EPS (Basic) Growth (5y) (2017 - 2026)
Tempest Therapeutics (TPST) EPS (Basic) Growth (5y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - |
| 10 | Tempest Therapeutics | 4.46 Mn | 3.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 58.20% |
| Dec 31, 2025 | 69.20% |
| Sep 30, 2025 | -15.53% |
| Jun 30, 2025 | 44.69% |
| Mar 31, 2025 | 54.74% |
| Dec 31, 2024 | 67.52% |
| Sep 30, 2024 | 50.43% |
| Jun 30, 2024 | 48.20% |
| Mar 31, 2024 | 50.03% |
| Dec 31, 2023 | 84.26% |
| Sep 30, 2023 | 57.53% |
| Jun 30, 2023 | 59.10% |
| Mar 31, 2023 | 58.43% |
| Dec 31, 2022 | 56.78% |
| Sep 30, 2022 | 59.25% |
| Jun 30, 2022 | 62.98% |
| Mar 31, 2022 | 57.96% |
| Dec 31, 2021 | 63.69% |
| Sep 30, 2021 | 59.91% |
| Jun 30, 2021 | 44.05% |